Newly Listed BioAge Labs To Present At Investor Conferences, Expects Obesity Trial Data By Q3 2025

BioAge Labs Inc. (BIOA), a clinical-stage biopharmaceutical company developing therapies for metabolic diseases by targeting the biology of aging, is scheduled to participate in two major investor conferences next month, i.e., on Dec.3 and Dec.4.

The company CEO and co-founder, Kristen Fortney, will lead the presentation, followed by one-on-one meetings with investors.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com